StockData
Teva Pharmaceutical Industries Ltd logo

Teva Pharmaceutical Industries Ltd

TEVANYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/30
$41.31−0.19 (-0.46%)

Close on Oct 19, 2026Market cap $48.13BP/E 68.9Yield –

Teva Pharmaceutical Industries Depreciation Expense (Per EBITDA Reconciliation) by Quarter

Depreciation Expense (Per EBITDA Reconciliation) ($M)

Teva Pharmaceutical Industries Depreciation Expense (Per EBITDA Reconciliation): $106M in Q3 2026, up 1.0% from a year earlier.

Latest, Q3 2026
106
Period ended Sep 30, 2026
Change on a year earlier
+1.0%
105 in Q3 2025
History
20 quarters
Since Q4 2021
Sources
16
Documents cited below

Where the Q3 2026 figure comes from

“|| Depreciation | 106 | 105 | 311 | 306”

Source: Form 8-K Earnings Release (0001171843-26-007054) ↗

Reported in SEC Form 10-K / Form 10-Q / Form 8-K Earnings Releases.

quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedDepreciation Expense (Per EBITDA Reconciliation) ($M)Year on yearSource
Q3 2026Sep 30, 2026106+1.0%Form 8-K Earnings Release (0001171843-26-007054) ↗
Q2 2026Jun 30, 2026102-1.0%Form 8-K Earnings Release (0001171843-26-004974) ↗
Q1 2026Mar 31, 2026102+3.0%Form 8-K Earnings Release (0001171843-26-002796) ↗
Q4 2025Dec 31, 2025114-4.2%Form 8-K Earnings Release (0001171843-26-000462) ↗
Q3 2025Sep 30, 2025105-7.1%Form 8-K Earnings Release (0001171843-25-007000) ↗
Q2 2025Jun 30, 2025103-8.8%Form 8-K Earnings Release (0001171843-25-004808) ↗
Q1 2025Mar 31, 202599-16.8%Form 8-K Earnings Release (0001171843-25-002849) ↗
Q4 2024Dec 31, 2024119-0.8%Form 8-K Earnings Release (0001171843-25-000493) ↗
Q3 2024Sep 30, 2024113-18.7%Form 8-K Earnings Release (0001171843-24-006034) ↗
Q2 2024Jun 30, 2024113-18.1%Form 8-K Earnings Release (0001171843-24-004270) ↗
Q1 2024Mar 31, 2024119-14.4%Form 8-K Earnings Release (0001193125-24-133759) ↗
Q4 2023Dec 31, 2023120-20.0%Form 8-K Earnings Release (0001157523-24-000137) ↗
Q3 2023Sep 30, 2023139-10.9%Form 8-K Earnings Release (0001157523-23-001677) ↗
Q2 2023Jun 30, 2023138-6.1%Form 8-K Earnings Release (0001157523-23-001212) ↗
Q1 2023Mar 31, 2023139+13.0%Form 8-K Earnings Release (0001157523-23-000797) ↗
Q4 2022Dec 31, 2022150+13.6%Form 8-K Earnings Release (0001157523-23-000205) ↗

Cite this data

StockData. (2026). Teva Pharmaceutical Industries Depreciation Expense (Per EBITDA Reconciliation) ($M), quarterly Q4 2021–Q3 2026 [Data set]. Compiled from Teva Pharmaceutical Industries SEC filings and investor materials. https://stockdatahq.com/stocks/teva/kpis/ng-depr

See every metric in the Teva Pharmaceutical Industries KPI table. Data updated Nov 10, 2026.

See a number that looks wrong?